185147-17-5

Usage

Uses

Used in Pharmaceutical Applications:
5-Hydroxy Vioxx is used as a metabolite in the pharmaceutical industry for its role in the biotransformation of Rofecoxib (Vioxx). Its dependency on the subcellular fraction and the redox system used makes it a valuable compound for studying the metabolic pathways and interactions of Vioxx within the body.
Used in Research and Development:
In the field of research and development, 5-Hydroxy Vioxx serves as a crucial compound for understanding the metabolic processes and potential effects of Vioxx. Its dependency on the subcellular fraction and the redox system used provides insights into the biotransformation mechanisms and can contribute to the development of new drugs or modifications to existing ones.
Used in Toxicology Studies:
5-Hydroxy Vioxx is used as a metabolite in toxicology studies to evaluate the safety and potential side effects of Vioxx. Understanding the biotransformation process and the factors influencing it, such as the subcellular fraction and the redox system, can help in assessing the risks associated with the use of Vioxx and guide the development of safer alternatives.
Used in Drug Metabolism Studies:
In the field of drug metabolism, 5-Hydroxy Vioxx is used as a key metabolite to study the metabolic fate of Vioxx in the body. The dependency of its biotransformation on the subcellular fraction and the redox system used can provide valuable information on the metabolic pathways and help in optimizing drug dosages and formulations for better efficacy and safety.
Used in Drug Interaction Studies:
5-Hydroxy Vioxx is used as a metabolite in drug interaction studies to investigate the potential effects of Vioxx on other medications or substances. Understanding the biotransformation process and its dependency on the subcellular fraction and the redox system can help in identifying possible drug interactions and their implications on patient health.

InChI:InChI=1/C17H16O5S/c1-23(20,21)13-9-7-12(8-10-13)15-14(16(18)22-17(15)19)11-5-3-2-4-6-11/h2-10,14-15,17,19H,1H3

Upstream product

• 162011-90-7 rofecoxib 
• 691005-66-0 (+/-)-5-bromo-4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one 
• 185147-16-4 Benzoic acid, 3-(4-(methylsulfonyl)phenyl)-5-oxo-4-phenyl-2,5-dihydrofuran-2-yl ester 
• 1778-09-2 4-(Methylthio)acetophenone 
• 42445-46-5 2-bromo-1-(4-methylsulfanyl-phenyl)-ethanone 

Downstream Products

• 213764-15-9 5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one 
• 213763-81-6 2-cyclopropylmethyl-5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one 
• 308364-83-2 5-Hydroxyrofecoxib glucuronide 

Relevant academic research and scientific papers

PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE

The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.

Facile air oxidation of the conjugate base of rofecoxib (Vioxx), a possible contributor to chronic human toxicity

The COX-2 inhibitor rofecoxib (Vioxx, 1) ionizes under physiological conditions to an anion that reacts readily with dioxygen to form inter alia the reactive maleic anhydride derivative 6, a potentially toxic compound.

Pyridazinones as selective cyclooxygenase-2 inhibitors

Pyridazinone was found to be an excellent core template for selective COX-2 inhibitors. Two potent, selective and orally active COX-2 inhibitors, which were highly efficacious in rat paw edema and rat pyresis models, have been obtained.

Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx(TM))

Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx(TM)) were prepared by synthetic or biosynthetic methods. Metabolites include products of oxidation, glucuronidation, reduction and hydrolytic ring opening. Based on an in vitro whole blood assay

Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.